Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

New mechanism helps cancer cells selectively produce proteins that drive tumor growth (opens in a new tab)

news-medical.net · 2026-10-29

Short answerEvidenceSource

Short answer

Not assessed

Check incomplete.

We found a likely source study, but its evidence could not be prepared for claim review. The article's claims remain unverified.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Source study identified.

A source study was identified, but the study's evidence could not be prepared for claim assessment. No claim verdicts are available.

View article claims
3
Then inspect each claim

Evidence layer

Claim by claim

A source study was identified, but the study's evidence could not be prepared for claim assessment. The claims below have not been assessed.

Claim 1 of 7Not checkedA previously unknown mechanism helps cancer cells selectively produce proteins that drive tumor growth, such as KRAS, in common cancers.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 2 of 7Not checkedThe study found that the METTL13 enzyme facilitates the production of important growth-driving proteins by helping cancer cells read codons more efficiently.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 3 of 7Not checkedMETTL13 did not broadly increase production of all proteins, but selectively enhanced a subset, many involved in cancer growth and survival.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 4 of 7Not checkedReducing or removing METTL13 lowered levels of KRAS and other cancer-driving proteins and slowed tumor growth in several preclinical cancer models.View evidenceHide evidence

As statedseveral preclinical cancer models

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 5 of 7Not checkedIn KRAS-mutant lung cancer models, including tumors resistant to the KRAS inhibitor sotorasib, METTL13 loss slowed tumor growth, restored treatment sensitivity, and significantly extended survival.View evidenceHide evidence

As statedsignificantly extended survival

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 6 of 7Not checkedPatients whose tumors had higher METTL13 activity tended to have poorer responses to KRAS inhibitors, suggesting the pathway may contribute to treatment resistance.View evidenceHide evidence

As statedpoorer responses

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 7 of 7Not checkedThe findings are preclinical and require further validation before clinical translation.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Methylated eEF1A selectively decodes mRNA to shape cancer proteomes

Nature Cell Biology · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 41 candidate papers

And 35 more candidates considered.